N/A N=40 Neuromonitoring During the Latarjet Procedure
Shoulder Instability · Iatrogenic Nerve Injury
Primary: Neurologic Complication Rate After Latarjet Procedure — 7 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=521 Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
Metastatic Breast Cancer
Primary: Progression-Free Survival (PFS) as Assessed by the Investigator — 9.2; 3.8 months — p=<0.000001
Phase 4 N=29 A Trial Comparing Efficacy and Safety of Voriconazole Administered With Therapeutic Drug Monitoring vs. Standard Dosing
Fungal Infection
Primary: Number of Participants With Treatment Failure — 1; 5 participants
Phase 1 N=22 First-in-human Study to Evaluate Safety, Tolerability and Pharmacokinetics of Various Doses of BCD-085 in Healthy Subjects
Healthy
Primary: Area Under the Plasma Concentration of BCD-085-time Curve From Zero (0) Hours to 1344 Hours After the Single Subcutaneous Injection of BCD-085 — 594222.00; 2262670.25…
Phase 3 N=628 Safety and Efficacy of Sublingual Immunotherapy (SLIT) Tablets in Grass Pollen Rhinoconjunctivitis
Allergy
Primary: Average Rhinoconjunctivitis Total Symptom Score — 4.72; 3.58; 3.74; 4.93 Units on a scale (range: 0 to 18) — p=0.0006
Phase 4 N=50 Efficacy of GXR as Adjunctive Therapy With Psycho-stimulant on Executive Function in Children With ADHD
Attention Deficit Hyperactivity Disorder
Primary: Effect of Adjunctive INTUNIV Extended Release Treatment on Executive Function as Assessed by Change From Baseline on the BRIEF-parent Questionnaires — -5.3; -6.9 units…
N/A N=451 A Study to Assess the Efficacy of Raltegravir (Isentress®), Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen)
HIV-1 Infection
Primary: Percentage of Participants With an HIV-1 Viral Load <50 Copies/mL After 48 Weeks of Raltegravir Treatment — 50.8; 74.7 Percentage of participants
Phase 2 N=38 CLOTBUST Hands-Free: A Phase I/II Pilot Safety Trial
Stroke
Primary: Number of Participants in Phase I Group With Blood-brain-barrier Disruption (BBB) as Measured by MRI of the Brain — 0 participants
Phase 1 N=94 Comparative Clinical Study of Pharmacokinetics, Tolerance and Safety of BCD-057 and Humira in Healthy Volunteers
Healthy
Primary: Maximum Concentration of Adalimumab After Single SC Injection of BCD-057/Humira — 4426; 4522 ng/ml
Phase 1 N=89 Efficacy and Safety of Sublingual Tablets of Grass Pollen Allergen Extract
Seasonal Allergic Rhinitis
Primary: Average of Rhinoconjunctivitis Total Symptom Score (ARTSS) ]0-4] Hours — 4.88; 6.84 Units on a scale (range: 0 to 18) — p=0.0003
Phase 2 N=396 Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Prostate Cancer
Primary: Progression Free Survival (PFS) — 19.4; 5.7 months — p=<0.0001
Phase 2 N=151 A Study in Subjects With Recurrent Malignant Glioma
Glioma
Primary: Progression Free Survival (PFS) Rate at Month 6 — 11.0; 21.2; 8.0; 7.6 Percentage of participants
Phase 2 N=108 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors
Extragonadal Germ Cell Tumor · Ovarian Cancer · Testicular Germ Cell Tumor
Primary: Overall Objective Response — 50; 4; 36; 8 participants
Phase 2 N=34 A Study of Metronidazole Cream in the Prevention and Treatment of Tarceva (Erlotinib)-Associated Rash
Non-Squamous Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Erlotinib Associated Rash Stratified by Severity Grade at Week 2 — 11; 22; 0; 33 percentage of participants
Phase 2 N=30 Anakinra to Prevent Adverse Post-infarction Remodeling (2)
Acute Myocardial Infarction · Heart Failure
Primary: Difference Between the Anakinra Arm and the Placebo Arm in Change in Left Ventricular End-systolic Volume Indices — 1.5; 1.0 mL/m2 — p=<0.05